Glucocorticoid regulation of rat diencephalon angiotensinogen production.

Endocrinology

Department of Physiology, University of California, San Francisco 94143-0444.

Published: February 1990

To investigate whether glucocorticoids can stimulate rat brain angiotensinogen production directly, we have studied the effect of dexamethasone on angiotensinogen secretion and angiotensinogen mRNA concentration in primary astroglial cultures from rat diencephalon. Dexamethasone stimulated angiotensinogen secretion by astroglial cells in a dose-related fashion. The half-maximally effective concentration was 11 nM, and the effect was blocked by RU 486, an antagonist of type II glucocorticoid receptors. This was similar to what was observed in rat hepatoma H4IIEC cells, where the half-maximally effective concentration of dexamethasone on angiotensinogen secretion was 10 nM. At maximal concentrations, dexamethasone increased angiotensinogen secretion and angiotensinogen mRNA concentration 2-fold in astroglial cells. In the hepatoma cells, however, the increase in angiotensinogen secretion was 5-fold. The in vivo diencephalon angiotensinogen mRNA concentration was decreased after adrenalectomy. Dexamethasone restored those levels to normal and induced a modest increase when the animals were killed 6 h after drug administration. In contrast, dexamethasone induced a robust increase in liver angiotensinogen mRNA concentration in the same animals. These results indicate that glucocorticoids increase angiotensinogen production through a direct receptor-mediated mechanism in both liver and brain. However, the angiotensinogen gene appears much more responsive to the action of glucocorticoids in liver than in brain.

Download full-text PDF

Source
http://dx.doi.org/10.1210/endo-126-2-963DOI Listing

Publication Analysis

Top Keywords

angiotensinogen secretion
20
angiotensinogen mrna
16
mrna concentration
16
angiotensinogen
13
angiotensinogen production
12
rat diencephalon
8
diencephalon angiotensinogen
8
brain angiotensinogen
8
dexamethasone angiotensinogen
8
secretion angiotensinogen
8

Similar Publications

Nocturnal polyuria is a major cause of nocturia, which affects quality of life. Aging-related decreases in nitric oxide production have been reported to contribute to salt-induced nocturnal polyuria. We posited that enhanced nitric oxide production from exercise could mitigate salt-induced nocturnal polyuria.

View Article and Find Full Text PDF

The Renin-Angiotensin System (RAS) is a complex neuroendocrine system consisting of a single precursor protein, angiotensinogen (AGT), which is processed into various peptide hormones, including the angiotensins [Ang I, Ang II, Ang III, Ang IV, Ang-(1-9), Ang-(1-7), Ang-(1-5), etc] and Alamandine-related peptides [Ang A, Alamandine, Ala-(1-5)], through intricate enzymatic pathways. Functionally, the RAS is divided into two axes with opposing effects: the classical axis, primarily consisting of Ang II acting through the AT receptor (ATR), and in contrast the protective axis, which includes the receptors Mas, ATR and MrgD and their respective ligands. A key area of RAS research is to gain a better understanding how signaling cascades elicited by these receptors lead to either "classical" or "protective" effects, as imbalances between the two axes can contribute to disease.

View Article and Find Full Text PDF

Small Interfering RNA Therapy for the Management and Prevention of Hypertension.

Curr Hypertens Rep

January 2025

Department of Pharmacy, The Second Clinical Medical College, The First Affiliated Hospital, Shenzhen People's Hospital, Jinan University, Southern University of Science and Technology), Shenzhen, China.

Purpose Of Review: To review currently existing knowledge on a new type of antihypertensive treatment, small interfering RNA (siRNA) targeting hepatic angiotensinogen.

Recent Findings: Targeting angiotensinogen synthesis in the liver with siRNA allows reaching a suppression of renin-angiotensin system (RAS) activity for up to 6 months after 1 injection. This might revolutionize antihypertensive treatment, as it could overcome non-adherence, the major reason for inadequate blood pressure control.

View Article and Find Full Text PDF

APOL1 Modulates Renin-Angiotensin System.

Biomolecules

December 2024

Department of Medicine and Feinstein Institute for Medical Research, Zucker School of Medicine, Hempstead, NY 11549, USA.

Patients carrying APOL1 risk alleles (G1 and G2) have a higher risk of developing Focal Segmental Glomerulosclerosis (FSGS); we hypothesized that escalated levels of miR193a contribute to kidney injury by activating renin-angiotensin system (RAS) in the APOL1 milieus. Differentiated podocytes (DPDs) stably expressing vector (V/DPD), G0 (G0/DPDs), G1 (G1/DPDs), and G2 (G2/DPDs) were evaluated for renin, Vitamin D receptor (VDR), and podocyte molecular markers (PDMMs, including WT1, Podocalyxin, Nephrin, and Cluster of Differentiation [CD]2 associated protein [AP]). G0/DPDs displayed attenuated renin but an enhanced expression of VDR and Wilms Tumor [WT]1, including other PDMMs; in contrast, G1/DPDs and G2/DPDs exhibited enhanced expression of renin but decreased expression of VDR and WT1, as well as other PDMMs (at both the protein and mRNA levels).

View Article and Find Full Text PDF

Background: Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum of phenotypes with associated disparate outcomes. We evaluate the impact of 'ongoing AKI' on prognosis and cardiorenal outcomes and describe predictors of 'ongoing AKI'.

Methods: A prospective multicentre observational study of patients admitted with ADHF requiring intravenous furosemide was completed, with urinary angiotensinogen (uAGT) measured at baseline.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!